Veeva Systems v. Tact.ai & Aktana: CRM Patent Dispute Ends in Settlement

📄 View Full Report 📥 Export PDF 🔗 Share ⭐ Save

In a closely watched patent infringement dispute involving life sciences CRM and AI-powered sales intelligence technology, Veeva Systems, Inc. v. Tact.ai Technologies, Inc. and Aktana, Inc. (Case No. 1:23-cv-01032) concluded with a negotiated dismissal in January 2025 — without a court ruling on the merits. Filed in the Delaware District Court on September 21, 2023, and closed 491 days later on January 24, 2025, the case centered on three U.S. patents covering intelligent data routing, messaging infrastructure, and digital engagement tools embedded in life sciences commercial platforms.

The outcome — a stipulated dismissal with prejudice between Veeva and Aktana, and a without-prejudice dismissal against Tact.ai — carries significant implications for companies competing in the AI-driven pharmaceutical CRM space. For patent attorneys and IP professionals, the case underscores how pre-trial resolution strategies, counterclaim structures, and multi-defendant dynamics shape the trajectory of commercial patent litigation in one of the most patent-active venues in the United States.

Case Overview

Veeva filed its complaint on September 21, 2023, choosing the District of Delaware — the nation’s preeminent venue for patent infringement litigation, known for its experienced judiciary, well-developed local patent rules, and efficient case management. The case was presided over by Chief Judge John F. Murphy. Notably, the docket reflects a Second Amended Complaint (D.I. 93), indicating Veeva refined its infringement theory and possibly its accused product set during the litigation — a procedural step suggesting active claim narrowing or the addition of newly identified infringement allegations. Aktana filed counterclaims comprising five counts.

The Parties

⚖️ Plaintiff

A publicly traded cloud software company, dominant provider of CRM, content management, and data solutions for the global life sciences industry.

🛡️ Co-Defendant

Provides AI-driven decision support and next-best-action recommendation engines for life sciences sales teams.

🛡️ Co-Defendant

Develops AI-powered voice and mobile assistant tools integrating with enterprise CRM systems for field sales representatives.

Patents at Issue

Veeva asserted three U.S. patents protecting core technical capabilities underlying enterprise CRM communication pipelines and AI-assisted field engagement workflows:

Veeva’s infringement claims targeted Tact Dynamic Insights, Tact Field Email, and Tact Presenter for MS Teams.

🔍

Developing AI-driven CRM tools?

Check if your technology might infringe these or related patents.

Run FTO Check →

The Verdict & Legal Analysis

Outcome

The case resolved through stipulated dismissal rather than a merits ruling. The final disposition breaks down as follows:

  • Veeva v. Aktana: Dismissed with prejudice as to Veeva’s claims and Aktana’s Counts I and II counterclaims — indicating a negotiated resolution, likely including confidential settlement terms.
  • Aktana’s Declaratory Judgment Counterclaims (Counts III, IV, V): Dismissed without prejudice as moot — meaning the underlying dispute between the parties was resolved sufficiently that these defensive claims no longer required adjudication.
  • Veeva v. Tact.ai: Dismissed without prejudice under FRCP 41(a)(1)(A)(i), as Tact.ai had not yet filed an answer to the Second Amended Complaint — preserving Veeva’s right to refile claims against Tact.ai in the future.
  • Attorneys’ fees and costs: Each party bears its own — a standard term in negotiated IP settlements indicating no prevailing party fee award under 35 U.S.C. § 285.

No specific financial settlement terms were disclosed in the public record.

Legal Significance

The with-prejudice dismissal between Veeva and Aktana strongly implies a binding resolution — whether a licensing agreement, a covenant not to sue, or a broader commercial arrangement. The simultaneous mootness dismissal of Aktana’s declaratory judgment counterclaims reinforces that the parties reached a comprehensive resolution extinguishing all live patent disputes between them.

The without-prejudice dismissal of Tact.ai — particularly before answer — is strategically significant. It suggests Veeva may have prioritized resolving the Aktana dispute first, or that Tact.ai’s commercial relevance to Veeva’s core claims diminished during litigation. Importantly, Veeva retains the ability to reassert these three patents against Tact.ai if circumstances change.

For claim construction and patent validity purposes, the absence of a merits ruling means this case creates no binding precedent regarding the scope of the three asserted patents. However, the patents themselves — particularly U.S. 11,501,313, with its more recent issuance and broader potential claim scope — remain active enforcement tools in Veeva’s IP portfolio.

Legal Representation

Plaintiff Veeva was represented by McCarter & English LLP, with attorneys Alexandra M. Joyce, Bradford C. Schulz, Daniel M. Silver, Hani A. Salameh, Jeffrey D. Smyth, Kate Roggio Buck, and Ming-Tao Yang.

Defendants were represented by Potter, Anderson & Corroon LLP, with attorneys Bindu Ann George Palapura, David Ellis Moore, John M. DiBaise, and Michael J. Sacksteder.

✍️

Drafting patents for AI-driven CRM?

Learn from this case. Use AI to draft stronger claims that can withstand litigation.

Try Patent Drafting →

Power Your Patent Strategy with Eureka IP

From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.

⚠️ Freedom to Operate (FTO) Analysis

This case highlights critical IP risks in AI-driven CRM technology. Choose your next step:

📋 Understand This Case’s Impact

Learn about the specific risks and implications from this litigation and the patents involved.

  • View all 3 asserted patents and their prosecution history
  • See the competitive landscape in life sciences CRM AI
  • Understand potential design-around strategies
📊 View Patent Landscape
⚠️
High Risk Area

AI-driven CRM messaging & engagement

📋
3 Asserted Patents

Core to life sciences CRM functionality

Strategic Pathways

Design-around options exist

✅ Key Takeaways

For Patent Attorneys & Litigators

Multi-patent, multi-defendant complaints in Delaware can resolve efficiently, reflecting sophisticated litigation management and aligning commercial incentives.

Search related case law →

Bifurcated dismissal outcomes (with vs. without prejudice for different defendants) are powerful tools for managing complex multi-party patent disputes.

Explore precedents →

Declaratory judgment counterclaims remain a viable and effective defensive lever, even when ultimately dismissed as moot.

Explore defensive strategies →

For IP Professionals & R&D Teams

Conduct FTO analysis against Veeva’s communication routing and engagement tracking patent families before launching CRM-adjacent tools in the life sciences market.

Start FTO analysis for my product →

The without-prejudice dismissal of Tact.ai means the commercial risk window for similar products remains open; monitor for future enforcement.

Track patent activity →

Strategic settlement offers opportunities for confidential licensing arrangements and elimination of ongoing litigation risk.

Try AI patent drafting →

Ready to Strengthen Your Patent Strategy?

Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.

⚖️ Disclaimer: This article is for informational purposes only and does not constitute legal advice. The analysis presented reflects publicly available case information and general legal principles. For specific advice regarding patent litigation, FTO analysis, or IP strategy, please consult a qualified patent attorney.